The Global Diabetes Care Devices Market was valued at USD 59.2 billion in 2025 and is estimated to grow at a CAGR of 12.4% to reach USD 188.8 billion by 2035.
Rising diabetes prevalence continues to create strong demand for advanced solutions that support effective disease management and long-term patient care. The global diabetes care devices market is also benefiting from increasing preference for minimally invasive and wearable technologies that improve patient comfort while enabling continuous health monitoring. These medical devices play an essential role in blood glucose monitoring, insulin administration, and overall diabetes management, allowing patients to better manage their condition through improved treatment accuracy and convenience. Growing financial support from both public and private organizations is further accelerating market expansion by encouraging prevention initiatives, early diagnosis programs, and long-term disease management strategies. Investments in digital healthcare infrastructure, wearable technologies, and connected medical devices continue to strengthen the overall diabetes care ecosystem while improving patient access to advanced treatment solutions. Rapid technological innovation remains a key market trend, with manufacturers focusing on developing cost-effective, user-friendly, and highly reliable diabetes care devices that deliver improved clinical performance and support better patient outcomes across diverse healthcare settings.
The devices segment generated USD 40.5 billion in 2025 and is anticipated to reach USD 130.9 billion by 2035, registering a CAGR of 12.6%, supported by increasing adoption of advanced diabetes management technologies. Continuous innovation in glucose monitoring systems and insulin delivery solutions continues to improve treatment precision, simplify disease management, and enhance patient compliance. Growing demand for accurate glucose monitoring and efficient insulin administration is expected to maintain strong growth throughout the forecast period.
The home care segment accounted for USD 26 billion in 2025. Rising emphasis on independent disease management, greater convenience, and long-term treatment efficiency continues to drive demand for home-based diabetes care solutions. The expansion of connected healthcare technologies, remote patient monitoring, and telehealth services has further strengthened this segment by enabling continuous health tracking and seamless communication between patients and healthcare professionals. Increasing preference for minimally invasive, easy-to-use devices is also supporting sustained adoption across home care environments.
North America Diabetes Care Devices Market captured 41.9% share in 2025. Market expansion across the region is being driven by the growing number of individuals living with diabetes and the increasing need for long-term disease management solutions. Rising rates of lifestyle-related health conditions, together with an aging population, continue to expand the patient base, creating sustained demand for advanced diabetes care technologies and connected medical devices.
Major companies operating in the global diabetes care devices market include Abbott Laboratories, ARKRAY, Ascensia Diabetes Care, B. Braun Melsungen, Becton Dickinson and Company, Bionime, DarioHealth, Dexcom, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche, Insulet, Medtronic, Nova Biomedical, Novo Nordisk, Pendiq, LifeScan, Sanofi, Sinocare, Tandem Diabetes Care, and Ypsomed Holding. Companies operating in the diabetes care devices market continue to strengthen their market position by investing heavily in research and development to introduce innovative, connected, and patient-centric solutions. Manufacturers are focusing on integrating digital health technologies, wearable platforms, and advanced data management capabilities to improve treatment outcomes and enhance patient engagement. Product portfolio expansion, continuous technological innovation, and development of minimally invasive devices remain important competitive strategies. Strategic partnerships, regulatory approvals, and broader geographic expansion are also helping companies increase market penetration and strengthen customer reach.
This product will be delivered within 2-4 business days.
Rising diabetes prevalence continues to create strong demand for advanced solutions that support effective disease management and long-term patient care. The global diabetes care devices market is also benefiting from increasing preference for minimally invasive and wearable technologies that improve patient comfort while enabling continuous health monitoring. These medical devices play an essential role in blood glucose monitoring, insulin administration, and overall diabetes management, allowing patients to better manage their condition through improved treatment accuracy and convenience. Growing financial support from both public and private organizations is further accelerating market expansion by encouraging prevention initiatives, early diagnosis programs, and long-term disease management strategies. Investments in digital healthcare infrastructure, wearable technologies, and connected medical devices continue to strengthen the overall diabetes care ecosystem while improving patient access to advanced treatment solutions. Rapid technological innovation remains a key market trend, with manufacturers focusing on developing cost-effective, user-friendly, and highly reliable diabetes care devices that deliver improved clinical performance and support better patient outcomes across diverse healthcare settings.
The devices segment generated USD 40.5 billion in 2025 and is anticipated to reach USD 130.9 billion by 2035, registering a CAGR of 12.6%, supported by increasing adoption of advanced diabetes management technologies. Continuous innovation in glucose monitoring systems and insulin delivery solutions continues to improve treatment precision, simplify disease management, and enhance patient compliance. Growing demand for accurate glucose monitoring and efficient insulin administration is expected to maintain strong growth throughout the forecast period.
The home care segment accounted for USD 26 billion in 2025. Rising emphasis on independent disease management, greater convenience, and long-term treatment efficiency continues to drive demand for home-based diabetes care solutions. The expansion of connected healthcare technologies, remote patient monitoring, and telehealth services has further strengthened this segment by enabling continuous health tracking and seamless communication between patients and healthcare professionals. Increasing preference for minimally invasive, easy-to-use devices is also supporting sustained adoption across home care environments.
North America Diabetes Care Devices Market captured 41.9% share in 2025. Market expansion across the region is being driven by the growing number of individuals living with diabetes and the increasing need for long-term disease management solutions. Rising rates of lifestyle-related health conditions, together with an aging population, continue to expand the patient base, creating sustained demand for advanced diabetes care technologies and connected medical devices.
Major companies operating in the global diabetes care devices market include Abbott Laboratories, ARKRAY, Ascensia Diabetes Care, B. Braun Melsungen, Becton Dickinson and Company, Bionime, DarioHealth, Dexcom, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche, Insulet, Medtronic, Nova Biomedical, Novo Nordisk, Pendiq, LifeScan, Sanofi, Sinocare, Tandem Diabetes Care, and Ypsomed Holding. Companies operating in the diabetes care devices market continue to strengthen their market position by investing heavily in research and development to introduce innovative, connected, and patient-centric solutions. Manufacturers are focusing on integrating digital health technologies, wearable platforms, and advanced data management capabilities to improve treatment outcomes and enhance patient engagement. Product portfolio expansion, continuous technological innovation, and development of minimally invasive devices remain important competitive strategies. Strategic partnerships, regulatory approvals, and broader geographic expansion are also helping companies increase market penetration and strengthen customer reach.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
- Abbott Laboratories
- ARKRAY
- Ascensia Diabetes Care
- B. Braun Melsungen
- Becton, Dickinson and Company
- Bionime
- DarioHealth
- Dexcom
- Dr. Reddy’s Laboratories
- Eli Lilly and Company
- F. Hoffmann-La Roche
- Insulet
- LifeScan
- Medtronic
- Nova Biomedical
- Novo Nordisk
- Pendiq
- Sanofi
- Sinocare
- Tandem Diabetes Care
- Ypsomed Holding
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 134 |
| Published | July 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 59.2 Billion |
| Forecasted Market Value ( USD | $ 188.8 Billion |
| Compound Annual Growth Rate | 12.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
